– Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis – Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy SAN DIEGO, Oct. 19, 2026 /PRNewswire/ — Protego…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
